J Korean Neurosurg Soc.  2015 Jun;57(6):422-427. 10.3340/jkns.2015.57.6.422.

Single Nucleotide Polymorphism in Patients with Moyamoya Disease

• Park YS

• KMID: 2191248
• DOI: http://doi.org/10.3340/jkns.2015.57.6.422

Abstract

Moyamoya disease (MMD) is a chronic, progressive, cerebrovascular occlusive disorder that displays various clinical features and results in cerebral infarct or hemorrhagic stroke. Specific genes associated with the disease have not yet been identified, making identification of at-risk patients difficult before clinical manifestation. Familial MMD is not uncommon, with as many as 15% of MMD patients having a family history of the disease, suggesting a genetic etiology. Studies of single nucleotide polymorphisms (SNPs) in MMD have mostly focused on mechanical stress on vessels, endothelium, and the relationship to atherosclerosis. In this review, we discuss SNPs studies targeting the genetic etiology of MMD. Genetic analyses in familial MMD and genome-wide association studies represent promising strategies for elucidating the pathophysiology of this condition. This review also discusses future research directions, not only to offer new insights into the origin of MMD, but also to enhance our understanding of the genetic aspects of MMD. There have been several SNP studies of MMD. Current SNP studies suggest a genetic contribution to MMD, but further reliable and replicable data are needed. A large cohort or family-based design would be important. Modern SNP studies of MMD depend on novel genetic, experimental, and database methods that will hopefully hasten the arrival of a consensus conclusion.

Keyword

Moyamoya disease; Single nucleotide polymorphism; Genetic; Stroke; Cerebrovascular disease

MeSH Terms

Atherosclerosis
Cohort Studies
Consensus
Endothelium
Genome-Wide Association Study
Humans
Moyamoya Disease*
Polymorphism, Single Nucleotide*
Stress, Mechanical
Stroke

Reference

1. Achrol AS, Guzman R, Lee M, Steinberg GK. Pathophysiology and genetic factors in moyamoya disease. Neurosurg Focus. 2009; 26:E4. PMID: 19335130.

2. Andreone V, Ciarmiello A, Fusco C, Ambrosanio G, Florio C, Linfante I. Moyamoya disease in Italian monozygotic twins. Neurology. 1999; 53:1332–1335. PMID: 10522894.

3. Aoyagi M, Fukai N, Sakamoto H, Shinkai T, Matsushima Y, Yamamoto M, et al. Altered cellular responses to serum mitogens, including platelet-derived growth factor, in cultured smooth muscle cells derived from arteries of patients with moyamoya disease. J Cell Physiol. 1991; 147:191–198. PMID: 2040653.

4. Aoyagi M, Ogami K, Matsushima Y, Shikata M, Yamamoto M, Yamamoto K. Human leukocyte antigen in patients with moyamoya disease. Stroke. 1995; 26:415–417. PMID: 7886716.

5. Asahi M, Wang X, Mori T, Sumii T, Jung JC, Moskowitz MA, et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci. 2001; 21:7724–7232. PMID: 11567062.

6. Baba T, Houkin K, Kuroda S. Novel epidemiological features of moyamoya disease. J Neurol Neurosurg Psychiatry. 2008; 79:900–904. PMID: 18077479.

7. Bonduel M, Hepner M, Sciuccati G, Torres AF, Tenembaum S. Prothrombotic disorders in children with moyamoya syndrome. Stroke. 2001; 32:1786–1792. PMID: 11486106.

8. Burke GM, Burke AM, Sherma AK, Hurley MC, Batjer HH, Bendok BR. Moyamoya disease : a summary. Neurosurg Focus. 2009; 26:E11. PMID: 19335127.

9. Cao Y, Hong A, Schulten H, Post MJ. Update on therapeutic neovascularization. Cardiovasc Res. 2005; 65:639–648. PMID: 15664390.

10. Cho HJ, Jung YH, Kim YD, Nam HS, Kim DS, Heo JH. The different infarct patterns between adulthood-onset and childhood-onset moyamoya disease. J Neurol Neurosurg Psychiatry. 2011; 82:38–40. PMID: 20587492.

11. Fujimura M, Watanabe M, Narisawa A, Shimizu H, Tominaga T. Increased expression of serum Matrix Metalloproteinase-9 in patients with moyamoya disease. Surg Neurol. 2009; 72:476–480. discussion 480PMID: 19147196.

12. Fukui M. Current state of study on moyamoya disease in Japan. Surg Neurol. 1997; 47:138–143. PMID: 9040816.

13. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem. 1998; 273:30336–30343. PMID: 9804796.

14. Guo DC, Papke CL, Tran-Fadulu V, Regalado ES, Avidan N, Johnson RJ, et al. Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease. Am J Hum Genet. 2009; 84:617–627. PMID: 19409525.

15. Han DH, Kwon OK, Byun BJ, Choi BY, Choi CW, Choi JU, et al. A co-operative study : clinical characteristics of 334 Korean patients with moyamoya disease treated at neurosurgical institutes (1976-1994). The Korean Society for Cerebrovascular Disease. Acta Neurochir (Wien). 2000; 142:1263–1273. discussion 1273-1274PMID: 11201642.

16. Han DH, Nam DH, Oh CW. Moyamoya disease in adults : characteristics of clinical presentation and outcome after encephalo-duro-arterio-synangiosis. Clin Neurol Neurosurg. 1997; 99(Suppl 2):S151–S155. PMID: 9409427.

17. Han H, Pyo CW, Yoo DS, Huh PW, Cho KS, Kim DS. Associations of Moyamoya patients with HLA class I and class II alleles in the Korean population. J Korean Med Sci. 2003; 18:876–880. PMID: 14676447.

18. Hojo M, Hoshimaru M, Miyamoto S, Taki W, Nagata I, Asahi M, et al. Role of transforming growth factor-beta1 in the pathogenesis of moyamoya disease. J Neurosurg. 1998; 89:623–629. PMID: 9761057.

19. Hong SH, Wang KC, Kim SK, Cho BK, Park MH. Association of HLA-DR and -DQ genes with familial Moyamoya disease in Koreans. J Korean Neurosurg Soc. 2009; 46:558–563. PMID: 20062572.

20. Hoshimaru M, Takahashi JA, Kikuchi H, Nagata I, Hatanaka M. Possible roles of basic fibroblast growth factor in the pathogenesis of moyamoya disease : an immunohistochemical study. J Neurosurg. 1991; 75:267–270. PMID: 2072165.

21. Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem. 1995; 270:19761–19766. PMID: 7544346.

22. Ikeda H, Sasaki T, Yoshimoto T, Fukui M, Arinami T. Mapping of a familial moyamoya disease gene to chromosome 3p24.2-p26. Am J Hum Genet. 1999; 64:533–537. PMID: 9973290.

23. Inoue TK, Ikezaki K, Sasazuki T, Matsushima T, Fukui M. Linkage analysis of moyamoya disease on chromosome 6. J Child Neurol. 2000; 15:179–182. PMID: 10757474.

24. Inoue TK, Ikezaki K, Sasazuki T, Ono T, Kamikawaji N, Matsushima T, et al. DNA typing of HLA in the patients with moyamoya disease. Jpn J Hum Genet. 1997; 42:507–515. PMID: 9560950.

25. Issa R, Krupinski J, Bujny T, Kumar S, Kaluza J, Kumar P. Vascular endothelial growth factor and its receptor, KDR, in human brain tissue after ischemic stroke. Lab Invest. 1999; 79:417–425. PMID: 10211994.

26. Jin KL, Mao XO, Nagayama T, Goldsmith PC, Greenberg DA. Induction of vascular endothelial growth factor and hypoxia-inducible factor-1alpha by global ischemia in rat brain. Neuroscience. 2000; 99:577–585. PMID: 11029549.

27. Kamada F, Aoki Y, Narisawa A, Abe Y, Komatsuzaki S, Kikuchi A, et al. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet. 2011; 56:34–40. PMID: 21048783.

28. Kastrup A, Schulz JB, Mader I, Dichgans J, Küker W. Diffusion-weighted MRI in patients with symptomatic internal carotid artery disease. J Neurol. 2002; 249:1168–1174. PMID: 12242534.

29. Kim SH, Hwang H, Chae JH, Kim KJ, Hwang YS, Lim BC. Ischemic stroke in a 7-month-old infant with antiphospholipid antibody and homozygous C677T methylenetetrahydrofolate reductase (MTHFR) polymorphism. J Child Neurol. 2010; 25:1047–1050. PMID: 20110213.

30. Kim SK, Yoo JI, Cho BK, Hong SJ, Kim YK, Moon JA, et al. Elevation of CRABP-I in the cerebrospinal fluid of patients with Moyamoya disease. Stroke. 2003; 34:2835–2841. PMID: 14605320.

31. Kitahara T, Okumura K, Semba A, Yamaura A, Makino H. Genetic and immunologic analysis on moya-moya. J Neurol Neurosurg Psychiatry. 1982; 45:1048–1052. PMID: 6983566.

32. Kraemer M, Horn PA, Roder C, Khan N, Diehl RR, Berlit P, et al. Analysis of human leucocyte antigen genes in Caucasian patients with idiopathic moyamoya angiopathy. Acta Neurochir (Wien). 2012; 154:445–454. PMID: 22234791.

33. Kuroda S, Hashimoto N, Yoshimoto T, Iwasaki Y. Research Committee on Moyamoya Disease in Japan. Radiological findings, clinical course, and outcome in asymptomatic moyamoya disease : results of multicenter survey in Japan. Stroke. 2007; 38:1430–1435. PMID: 17395863.

34. Kuroda S, Houkin K. Moyamoya disease : current concepts and future perspectives. Lancet Neurol. 2008; 7:1056–1066. PMID: 18940695.

35. Lee CZ, Xu B, Hashimoto T, McCulloch CE, Yang GY, Young WL. Doxycycline suppresses cerebral matrix metalloproteinase-9 and angiogenesis induced by focal hyperstimulation of vascular endothelial growth factor in a mouse model. Stroke. 2004; 35:1715–1719. PMID: 15166398.

36. Lee SR, Lo EH. Induction of caspase-mediated cell death by matrix metalloproteinases in cerebral endothelial cells after hypoxia-reoxygenation. J Cereb Blood Flow Metab. 2004; 24:720–727. PMID: 15241180.

37. Li H, Zhang ZS, Liu W, Yang WZ, Dong ZN, Ma MJ, et al. Association of a functional polymorphism in the MMP-3 gene with Moyamoya Disease in the Chinese Han population. Cerebrovasc Dis. 2010; 30:618–625. PMID: 20948207.

38. Liu C, Roder C, Schulte C, Kasuya H, Akagawa H, Nishizawa T, et al. Analysis of TGFB1 in European and Japanese Moyamoya disease patients. Eur J Med Genet. 2012; 55:531–534. PMID: 22659181.

39. Liu W, Hashikata H, Inoue K, Matsuura N, Mineharu Y, Kobayashi H, et al. A rare Asian founder polymorphism of Raptor may explain the high prevalence of moyamoya disease among East Asians and its low prevalence among Caucasians. Environ Health Prev Med. 2010; 15:94–104. PMID: 19921495.

40. Liu W, Morito D, Takashima S, Mineharu Y, Kobayashi H, Hitomi T, et al. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One. 2011; 6:e22542. PMID: 21799892.

41. Liu W, Senevirathna ST, Hitomi T, Kobayashi H, Roder C, Herzig R, et al. Genomewide association study identifies no major founder variant in Caucasian moyamoya disease. J Genet. 2013; 92:605–609. PMID: 24371184.

42. Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci. 2003; 4:399–415. PMID: 12728267.

43. Malek AM, Connors S, Robertson RL, Folkman J, Scott RM. Elevation of cerebrospinal fluid levels of basic fibroblast growth factor in moyamoya and central nervous system disorders. Pediatr Neurosurg. 1997; 27:182–189. PMID: 9577971.

44. McKasson MJ, Golomb MR. Two children with both arm ischemia and arterial ischemic stroke during the perinatal period. J Child Neurol. 2011; 26:1548–1554. PMID: 21862833.

45. Mineharu Y, Liu W, Inoue K, Matsuura N, Inoue S, Takenaka K, et al. Autosomal dominant moyamoya disease maps to chromosome 17q25.3. Neurology. 2008; 70(24 Pt 2):2357–2363. PMID: 18463369.

46. Miyatake S, Miyake N, Touho H, Nishimura-Tadaki A, Kondo Y, Okada I, et al. Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease. Neurology. 2012; 78:803–810. PMID: 22377813.

47. Miyatake S, Touho H, Miyake N, Ohba C, Doi H, Saitsu H, et al. Sibling cases of moyamoya disease having homozygous and heterozygous c.14576G>A variant in RNF213 showed varying clinical course and severity. J Hum Genet. 2012; 57:804–806. PMID: 22931863.

48. Miyawaki S, Imai H, Takayanagi S, Mukasa A, Nakatomi H, Saito N. Identification of a genetic variant common to moyamoya disease and intracranial major artery stenosis/occlusion. Stroke. 2012; 43:3371–3374. PMID: 23010677.

49. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993; 329:2002–2012. PMID: 7504210.

50. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature. 1995; 375:577–581. PMID: 7540725.

51. Nanba R, Kuroda S, Tada M, Ishikawa T, Houkin K, Iwasaki Y. Clinical features of familial moyamoya disease. Childs Nerv Syst. 2006; 22:258–262. PMID: 16195874.

52. Nanba R, Tada M, Kuroda S, Houkin K, Iwasaki Y. Sequence analysis and bioinformatics analysis of chromosome 17q25 in familial moyamoya disease. Childs Nerv Syst. 2005; 21:62–68. PMID: 15340753.

53. Park YS, Jeon YJ, Kim HS, Chae KY, Oh SH, Han IB, et al. The role of VEGF and KDR polymorphisms in moyamoya disease and collateral revascularization. PLoS One. 2012; 7:e47158. PMID: 23077562.

54. Park YS, Jeon YJ, Kim HS, Han IB, Choi JU, Kim DS, et al. The roles of methylenetetrahydrofolate reductase 677C>T and 1298A>C polymorphisms in moyamoya disease patients. Childs Nerv Syst. 2014; 30:1687–1695. PMID: 25098357.

55. Park YS, Jeon YJ, Kim HS, Han IB, Oh SH, Kim DS, et al. The GC + CC genotype at position -418 in TIMP-2 promoter and the -1575GA/-1306CC genotype in MMP-2 is genetic predisposing factors for prevalence of moyamoya disease. BMC Neurol. 2014; 14:180. PMID: 25280484.

56. Park YS, Min KT, Kim TG, Lee YH, Cheong HJ, Yeom IS, et al. Age-specific eNOS polymorphisms in moyamoya disease. Childs Nerv Syst. 2011; 27:1919–1926. PMID: 21691823.

57. Roder C, Peters V, Kasuya H, Nishizawa T, Wakita S, Berg D, et al. Analysis of ACTA2 in European Moyamoya disease patients. Eur J Paediatr Neurol. 2011; 15:117–122. PMID: 20970362.

58. Roder C, Peters V, Kasuya H, Nishizawa T, Takehara Y, Berg D, et al. Common genetic polymorphisms in moyamoya and atherosclerotic disease in Europeans. Childs Nerv Syst. 2011; 27:245–252. PMID: 20694560.

59. Roder C, Peters V, Kasuya H, Nishizawa T, Takehara Y, Berg D, et al. Polymorphisms in TGFB1 and PDGFRB are associated with Moyamoya disease in European patients. Acta Neurochir (Wien). 2010; 152:2153–2160. PMID: 20571834.

60. Ruel M, Khan TA, Voisine P, Bianchi C, Sellke FW. Vasomotor dysfunction after cardiac surgery. Eur J Cardiothorac Surg. 2004; 26:1002–1014. PMID: 15519196.

61. Sakamoto S, Kiura Y, Yamasaki F, Shibukawa M, Ohba S, Shrestha P, et al. Expression of vascular endothelial growth factor in dura mater of patients with moyamoya disease. Neurosurg Rev. 2008; 31:77–81. discussion 81PMID: 17912564.

62. Sakurai K, Horiuchi Y, Ikeda H, Ikezaki K, Yoshimoto T, Fukui M, et al. A novel susceptibility locus for moyamoya disease on chromosome 8q23. J Hum Genet. 2004; 49:278–281. PMID: 15362573.

63. Schork NJ, Fallin D, Lanchbury JS. Single nucleotide polymorphisms and the future of genetic epidemiology. Clin Genet. 2000; 58:250–264. PMID: 11076050.

64. Scott RM. Arteriovenous malformation and moyamoya disease. Childs Nerv Syst. 1997; 13:357. PMID: 9298267.

65. Skardoutsou A, Voudris KA, Mastroyianni S, Vagiakou E, Magoufis G, Koukoutsakis P. Moya moya syndrome in a child with pyruvate kinase deficiency and combined prothrombotic factors. J Child Neurol. 2007; 22:474–478. PMID: 17621533.

66. Sonobe S, Fujimura M, Niizuma K, Nishijima Y, Ito A, Shimizu H, et al. Temporal profile of the vascular anatomy evaluated by 9.4-T magnetic resonance angiography and histopathological analysis in mice lacking RNF213 : a susceptibility gene for moyamoya disease. Brain Res. 2014; 1552:64–71. PMID: 24440776.

67. Starke RM, Komotar RJ, Connolly ES. Optimal surgical treatment for moyamoya disease in adults : direct versus indirect bypass. Neurosurg Focus. 2009; 26:E8. PMID: 19335134.

68. Takekawa Y, Umezawa T, Ueno Y, Sawada T, Kobayashi M. Pathological and immunohistochemical findings of an autopsy case of adult moyamoya disease. Neuropathology. 2004; 24:236–242. PMID: 15484702.

69. Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem. 1996; 271:603–606. PMID: 8557658.

70. Wakai K, Tamakoshi A, Ikezaki K, Fukui M, Kawamura T, Aoki R, et al. Epidemiological features of moyamoya disease in Japan : findings from a nationwide survey. Clin Neurol Neurosurg. 1997; 99(Suppl 2):S1–S5. PMID: 9409395.

71. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem. 1994; 269:26988–26995. PMID: 7929439.

72. Wang X, Zhang Z, Liu W, Xiong Y, Sun W, Huang X, et al. Impacts and interactions of PDGFRB, MMP-3, TIMP-2, and RNF213 polymorphisms on the risk of Moyamoya disease in Han Chinese human subjects. Gene. 2013; 526:437–442. PMID: 23769926.

73. Weinberg DG, Arnaout OM, Rahme RJ, Aoun SG, Batjer HH, Bendok BR. Moyamoya disease : a review of histopathology, biochemistry, and genetics. Neurosurg Focus. 2011; 30:E20. PMID: 21631222.

74. Wu Z, Jiang H, Zhang L, Xu X, Zhang X, Kang Z, et al. Molecular analysis of RNF213 gene for moyamoya disease in the Chinese Han population. PLoS One. 2012; 7:e48179. PMID: 23110205.

75. Yamamoto M, Aoyagi M, Fukai N, Matsushima Y, Yamamoto K. Differences in cellular responses to mitogens in arterial smooth muscle cells derived from patients with moyamoya disease. Stroke. 1998; 29:1188–1193. PMID: 9626293.

76. Yamashita M, Oka K, Tanaka K. Histopathology of the brain vascular network in moyamoya disease. Stroke. 1983; 14:50–58. PMID: 6823686.

77. Yamauchi T, Tada M, Houkin K, Tanaka T, Nakamura Y, Kuroda S, et al. Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25. Stroke. 2000; 31:930–935. PMID: 10754001.

78. Yoshimoto T, Houkin K, Takahashi A, Abe H. Angiogenic factors in moyamoya disease. Stroke. 1996; 27:2160–2165. PMID: 8969773.